Efstathiou, E <br/><br/>
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.  [electronic resource] 

 -  Urology  Jan 2005 
 - 126-30 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1527-9995 
<br/><br/><label>Standard No.: </label>10.1016/j.urology.2004.08.041  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--blood<br/>Aged<br/>Aged, 80 and over<br/>Alopecia--chemically induced<br/>Androgen Antagonists--therapeutic use<br/>Antineoplastic Agents, Hormonal--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Biomarkers, Tumor--blood<br/>Bone Neoplasms--drug therapy<br/>Combined Modality Therapy<br/>Diphosphonates--administration & dosage<br/>Disease Progression<br/>Disease-Free Survival<br/>Docetaxel<br/>Drug Resistance, Neoplasm<br/>Estramustine--administration & dosage<br/>Humans<br/>Imidazoles--administration & dosage<br/>Life Tables<br/>Liver Neoplasms--drug therapy<br/>Lung Neoplasms--drug therapy<br/>Lymphatic Metastasis<br/>Male<br/>Middle Aged<br/>Neoplasm Proteins--blood<br/>Neutropenia--chemically induced<br/>Orchiectomy<br/>Pain--drug therapy<br/>Palliative Care<br/>Prostate-Specific Antigen--blood<br/>Prostatic Neoplasms--blood<br/>Radiotherapy, High-Energy<br/>Remission Induction<br/>Survival Analysis<br/>Taxoids--administration & dosage<br/>Treatment Outcome<br/>Zoledronic Acid